Literature DB >> 20027112

Clinical and genetic aspects of neurofibromatosis 1.

Kimberly Jett1, Jan M Friedman.   

Abstract

Neurofibromatosis 1 is an autosomal dominant disorder characterized by multiple café-au-lait spots, axillary and inguinal freckling, multiple cutaneous neurofibromas, and iris Lisch nodules. Learning disabilities are present in at least 50% of individuals with neurofibromatosis 1. Less common but potentially more serious manifestations include plexiform neurofibromas, optic nerve and other central nervous system gliomas, malignant peripheral nerve sheath tumors, scoliosis, tibial dysplasia, and vasculopathy. The diagnosis of neurofibromatosis 1 is usually based on clinical findings. Neurofibromatosis 1, one of the most common Mendelian disorders, is caused by heterozygous mutations of the NF1 gene. Almost one half of all affected individuals have de novo mutations. Molecular genetic testing is available clinically but is infrequently needed for diagnosis. Disease management includes referral to specialists for treatment of complications involving the eye, central or peripheral nervous system, cardiovascular system, spine, or long bones. Surgery to remove both benign and malignant tumors or to correct skeletal manifestations is sometimes warranted. Annual physical examination by a physician familiar with the disorder is recommended. Other recommendations include ophthalmologic examinations annually in children and less frequently in adults, regular developmental assessment in children, regular blood pressure monitoring, and magnetic resonance imaging for follow-up of clinically suspected intracranial and other internal tumors.

Entities:  

Mesh:

Year:  2010        PMID: 20027112     DOI: 10.1097/GIM.0b013e3181bf15e3

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  138 in total

1.  Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis.

Authors:  Jacob L Jaremko; Peter J MacMahon; Martin Torriani; Vanessa L Merker; Victor F Mautner; Scott R Plotkin; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2011-12-07       Impact factor: 2.199

2.  Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas.

Authors:  Boaz Karmazyn; Mervyn D Cohen; Samuel Gregory Jennings; Kent A Robertson
Journal:  Pediatr Radiol       Date:  2012-06-22

3.  Perioperative management of neurofibromatosis type 1.

Authors:  Charles J Fox; Samir Tomajian; Aaron J Kaye; Stephanie Russo; Jacqueline Volpi Abadie; Alan D Kaye
Journal:  Ochsner J       Date:  2012

4.  High prevalence of elevated blood pressure among children with neurofibromatosis type 1.

Authors:  Tom Dubov; Hagit Toledano-Alhadef; Gil Chernin; Shlomi Constantini; Roxana Cleper; Shay Ben-Shachar
Journal:  Pediatr Nephrol       Date:  2015-08-28       Impact factor: 3.714

5.  Neurofibromatosis: chronological history and current issues.

Authors:  João Roberto Antônio; Eny Maria Goloni-Bertollo; Lívia Arroyo Trídico
Journal:  An Bras Dermatol       Date:  2013 May-Jun       Impact factor: 1.896

6.  Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.

Authors:  Edwin Jousma; Tilat A Rizvi; Jianqiang Wu; David Janhofer; Eva Dombi; Richard S Dunn; Mi-Ok Kim; Andrea R Masters; David R Jones; Timothy P Cripe; Nancy Ratner
Journal:  Pediatr Blood Cancer       Date:  2015-04-22       Impact factor: 3.167

7.  NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.

Authors:  Joseph A Toonen; Corina Anastasaki; Laura J Smithson; Scott M Gianino; Kairong Li; Robert A Kesterson; David H Gutmann
Journal:  Hum Mol Genet       Date:  2016-02-16       Impact factor: 6.150

8.  Giant lumbar meningocele in type-1 neurofibromatosis.

Authors:  M S Themistocleous; I K Antoniadis; D E Sakas
Journal:  Hippokratia       Date:  2017 Jan-Mar       Impact factor: 0.471

9.  Treatment of neurofibromatosis type 1.

Authors:  Caterina Sabatini; Donatella Milani; Francesca Menni; Gianluca Tadini; Susanna Esposito
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

10.  Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia.

Authors:  Yangsook Song Green; Timothy Sargis; Ethan Conrad Reichert; Eleanor Rudasi; Daniel Fuja; Eric Jonasch; Mei Yee Koh
Journal:  Mol Cancer Res       Date:  2019-01-31       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.